CG Oncology says Phase 3 BOND-003 data for cretostimogene in BCG-unresponsive bladder cancer publish in Lancet Oncology
CGON•Potential regulatory path
Data support a potential regulatory path for cretostimogene, positioning it as a possible foundational monotherapy in NMIBC.
Bladder preservation and safety findings
Bladder preservation remained high through two years, supporting a bladder-sparing alternative to cystectomy for many patients.
The safety profile was favorable, with no severe treatment-related events reported and rapid resolution of side effects.
Phase 3 BOND-003 results published in The Lancet Oncology
CG Oncology reported publication of pivotal Phase 3 BOND-003 Cohort C results in The Lancet Oncology; results were already presented via the journal release.
The study showed cretostimogene delivered durable complete responses in high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
